A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms TROPOS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Nov 2017 According to an AstraZeneca media release, full data from the study will be presented at a forthcoming medical meeting.
    • 01 Nov 2017 Primary endpoint has not been met. (Percent change from baseline in the daily, average, OCS dose at week 40 post randomization while not losing asthma control.), according to an AstraZeneca media release.
    • 26 Sep 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top